This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.
Licensing
Definium Therapeutics (DFTX) stock skyrocketed Monday after the biotech company's psychedelics-based depression treatment scored a "best-case" win in final-phase testing. The company is testing an orally disintegrating tablet of lysergide, commonly known as LSD, in patients with major depressive disorder. Those patients with major depressive disorder, or MDD, haven't responded to at least two prior depression treatments. Patients treated with…
